Publications by authors named "A F Oger"
Background: Urinary tract infections are common affections, especially for women. Difficult access to a general practitioner to obtain a prescription has led France to offer dispensing under protocol by community pharmacists. The primary objective of this study is to evaluate the effectiveness of a pharmacist care protocol provided to manage women with urinary tract infection symptoms.
View Article and Find Full Text PDFAlginate oligosaccharides enhance the antifungal activity of nystatin against candidal biofilms.
Front Cell Infect Microbiol
February 2023
Background: The increasing prevalence of invasive fungal infections in immuno-compromised patients is a considerable cause of morbidity and mortality. With the rapid emergence of antifungal resistance and an inadequate pipeline of new therapies, novel treatment strategies are now urgently required.
Methods: The antifungal activity of the alginate oligosaccharide OligoG in conjunction with nystatin was tested against a range of spp.
Article Synopsis
- Aujeszky’s disease virus (ADV) is a significant neurological infection impacting animal health and the economy, particularly in livestock.
- Researchers conducted a serological screening for anti-ADV antibodies in muscle fluid from wild boars in southeastern France over two hunting seasons, finding that 30.33% of the 399 tested boars tested positive.
- The study revealed that geographical location and age significantly influenced ADV seroprevalence, highlighting the role of wild boars in the virus's epidemiology in the region.
Ebola is the most vicious virus in Africa. International organisations have worked to contain the various outbreaks and a vaccine is being administered to the population. This virus survives in a context where the African continent must face the new Covid-19 pandemic.
View Article and Find Full Text PDFBackground: The oral explanation (OE) is a critical event during new marketing authorisation procedures in the European Union (EU). The primary objective of the present study was to investigate how many procedures, having an OE in front of the Committee for Medicinal Products for Human Use (CHMP), resulted in a regulatory approval for oncology products.
Methods: Procedures for new marketing authorisation applications (MAAs) and Type II variations (new indication) for oncology products with at least one OE (with or without a Scientific Advisory Group (SAG) meeting) and for which the outcome took place between 31 January 2016 to 31 January 2020 were included in the analysis.